Literature DB >> 3338642

Serum glucose concentration as a modulator of interdigestive gastric motility.

J L Barnett1, C Owyang.   

Abstract

The objective of this study was to examine the effect of serum glucose concentration on interdigestive gastrointestinal motility and plasma motilin levels in humans. Motility studies were performed for a 3-h baseline period and a 3-h test period during which serum glucose levels were maintained with a glucose clamp at 250, 175, 140, or 120 mg/dl. During the basal recording, three phases of the interdigestive migrating motor complex (MMC) were easily recognizable, with a mean cycle duration of 97 +/- 12 min. Plasma motilin levels fluctuated in phase with the MMC. Gastric contractions were nearly absent at a serum glucose level of 250 mg/dl and markedly reduced at 175 and 140 mg/dl. Gastric phase III activity was inhibited during these infusions. Gastric contractions and phase III activity were not affected by glucose infusion at 120 mg/dl. In contrast, the frequency of duodenal phase III activity was unchanged at all levels of glucose infusion. Mean motilin levels were significantly reduced during glucose infusion at 250 and 175 mg/dl (p less than 0.05), but not at 140 and 120 mg/dl. We conclude that hyperglycemia inhibits the occurrence of the MMC in the stomach and suppresses plasma motilin levels. The differential sensitivity of motility and motilin concentration to different degrees of hyperglycemia suggests that hyperglycemia can inhibit antral motility independent of plasma motilin. In contrast, the duodenal MMC appears to be insensitive to hyperglycemia. This suggests that the antral and duodenal MMCs are mediated by different mechanisms. Our observations indicate the importance of serum glucose in regulating gastric motility.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3338642     DOI: 10.1016/0016-5085(88)90248-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  66 in total

1.  Hyperglycaemia stimulates pyloric motility in normal subjects.

Authors:  R Fraser; M Horowitz; J Dent
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

2.  Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus.

Authors:  R J Fraser; M Horowitz; A F Maddox; P E Harding; B E Chatterton; J Dent
Journal:  Diabetologia       Date:  1990-11       Impact factor: 10.122

3.  Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus.

Authors:  M Horowitz; A F Maddox; J M Wishart; P E Harding; B E Chatterton; D J Shearman
Journal:  Eur J Nucl Med       Date:  1991

4.  Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus.

Authors:  M Samsom; L M Akkermans; R J Jebbink; H van Isselt; G P vanBerge-Henegouwen; A J Smout
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

Review 5.  Gastroparesis--current concepts and considerations.

Authors:  William L Hasler
Journal:  Medscape J Med       Date:  2008-01-23

Review 6.  Pathophysiology and management of diabetic gastropathy: a guide for endocrinologists.

Authors:  Paul Kuo; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  The effect of hyperglycaemia on the absorption of glibenclamide in patients with non-insulin-dependent diabetes mellitus.

Authors:  A Hoffman; Y Fischer; D Gilhar; I Raz
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 8.  Small bowel motility: ready for prime time?

Authors:  E E Soffer
Journal:  Curr Gastroenterol Rep       Date:  2000-10

9.  The effect of acute hyperglycaemia on small intestinal motility in normal subjects.

Authors:  A Russo; R Fraser; M Horowitz
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

Review 10.  Gastrointestinal disturbances in diabetes.

Authors:  Manju Chandran; Neelima V Chu; Steven V Edelman
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.